High Evidence
Research Overview
Survodutide Research for Obesity
An evidence-based overview of research examining Survodutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2 dose-finding RCT (N=387) demonstrated dose-dependent weight loss, reaching 14.9% at 46 weeks with the 4.8mg dose vs 2.8% with placebo. Phase 3 SYNCHRONIZE-1 and -2 trials are ongoing with results expected 2026.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Survodutide may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.